Sutro Biopharma (STRO)
(Delayed Data from NSDQ)
$3.42 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.42 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
STRO 3.42 0.00(0.00%)
Will STRO be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for STRO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for STRO
Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates
Here's Why Sutro Biopharma (STRO) Is a Great 'Buy the Bottom' Stock Now
STRO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates
Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?
Why Sutro Biopharma (STRO) Might Surprise This Earnings Season
Other News for STRO
CVAC, SBNY and CRMD are among after hour movers
Ipsen And Sutro Partnering On ADCs Is A Deal Offering Opportunities For Investors
Sutro Biopharma price target lowered by $7 at Truist, here's why
Wall Street Analysts Are Bullish on Top Healthcare Picks
Sutro Biopharma price target lowered by $1 at Piper Sandler, here's why